OMV derived from AD patients can cross the BBB, promote microglia activation and inflammation, promote tau hyper-phosphorylation, and impair cognitive function when administered to wild-type mice (Wei et al., 2020). This evidence concerns the gene MAPT and Alzheimer disease.